Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

Humanwell Healthcare (Group) Co., Ltd.

Medshine Discovery Inc.

Wuhan Optics Valley Humanwell Bio-Pharmaceutical Co., Ltd.

Hubei Biological Medicine Industrial Technology Institute Co., Ltd.

Wuhan Chemligand Bio-Pharmaceutical Co., Ltd.

Grand Pharma (China) Co., Ltd.

Humanwell Healthcare Co., Ltd.

Lu Huang

Yong Xu

Xuehai Wang

Ronghua Tu

Hailiang Chen

Wenjie Sun

Shuhui Chen

Yong Wang

Lie Li

Cailin Wang

Jie Shen

Zhongwen Yang

Yang Yue

Qiang Xiao

Charles Z Ding

Zheng Wang

Cong Wang

Hui Liu

Weidong Li

Jing Yang

Yang YuE

Hua Tian

Yanping Yu

Jimeng Wang

Biao Deng

Li'e Li

Guoping Hu

Yan Chen

Chengde Wu

Yi Zhang

Wei Li

Zhaozhong Ding

Chunli Shen

Jian Li

Zhibo Zhang

Bo Yang

Jianzhong Zhou

Wen Zhou

Jie Li

Jing Tang

Gang Chen

Jianming Zhou

Nengyang Shi

Xuwen Zhang

Zhenyu He

Jing Yu

Quan Liu

Rubin Cao

Yun Feng

Zhaoze Fan

Xijun Sheng

Chengbing Yang

Xiaolin Zhang

Tianci Huang

Hangui Xia

Guofan Xie

Zhiqiang Qian

Haiming Geng

Diliang Guo

Gang Li

Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1, 5-alpha]benzimidazole compound and the preparation method and intermediate thereof. The 4H-pyrazolo[1,5-alpha]benzimidazole compound has the structure of Compound 2. 

Salt type and crystal type of 4h-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof

The present invention provides a pyrimidine derivative and a use thereof. The pyrimidine derivative is the compound shown in formula I or a pharmaceutically acceptable salt, hydrate, solvate, metabolite or prodrug thereof, wherein, R, R, R, Rand Rare, for example, as defined in the specification. The compound can act as an ALK inhibitor, and is for preparing an anti-tumor medicament for suppressing an anaplastic lymphoma kinase. 

Pyrimidine derivative and use thereof

Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV). 

BTK inhibitor

Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1,5-alpha]benzimidazole compound and a preparation method and intermediate thereof. The 4H-pyrazolo[1,5-alpha]benzimidazole compound is represented by formula I: 

Salt type and crystal type of 4H-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof

Disclosed is a series of analogs of 4H-pyrazolo[1,5-&#x3b1;]benzimidazole compound as PARP inhibitors. In particular, disclosed in the invention is a compound as shown by formula (I) or a pharmaceutically acceptable salt thereof as a PARP inhibitor.

Analogues of 4H-pyrazolo[1,5-a] benzimidazole compound as PARP inhibitors

A capsule containing total flavonoids of, a method for preparing the same and a use of the capsule containing total flavonoids ofare provided. Specifically, the capsule includes total flavonoids ofprovided in a form of alcohol extract ofand a pharmaceutically acceptable excipient.

Capsule containing total flavonoids of desmodium styracifolium, method for preparing the same and use

A method of preparation of 5,6-dimethylxanthone-4-acetic acid (DMXAA) and derivatives thereof. The derivatives are represented by formula (I), wherein R represents totally 1 to 2 substitutes at 1, 2, 3, 7, and 8 position selected from a lower alkyl, halogen, CF, CN, NO, NH, CHCOOH, OR, OH, NHSOR, SR, CHCONHRor NHR, and Rrepresents a lower alkyl, or a lower alkyl having OH, NH, or OCH. The invention further provides a pharmaceutical composition having such derivatives used as excellent antitumor and antibacterial agents. 

5,6-dimethyl xanthone-4-acetic acid derivatives and method of preparing the same

Growing community of inventors

Wuhan, China

Lu Huang